Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07464145
What this trial is testing

NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc. 393
Not applicableStudy completedNCT07642102
What this trial is testing

Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Transurethral Resection of Bladder Tumor
Ain Shams University 70
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Large-scale testing (Phase 3)WithdrawnNCT07342517
What this trial is testing

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT01108055
What this trial is testing

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Who this might be right for
Bladder CancerBladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)+2 more
Sandy Srinivas 43
Large-scale testing (Phase 3)Ended earlyNCT00384891
What this trial is testing

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Who this might be right for
Urinary Bladder DiseasesUrinary Bladder NeoplasmsUrinary Bladder Cancer+5 more
Medical Enterprises Europe B.V. 190
Large-scale testing (Phase 3)Ended earlyNCT02982395
What this trial is testing

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Samyang Biopharmaceuticals Corporation 36
Large-scale testing (Phase 3)WithdrawnNCT02254915
What this trial is testing

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I

Who this might be right for
Urinary Bladder NeoplasmsUrologic NeoplasmsUrogenital Neoplasms+4 more
Medical Enterprises Europe B.V.